Cargando…

Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: The Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial showed that ticagrelor-aspirin combination therapy reduced the risk of stroke compared with a clopidogrel-aspirin combination among carriers of CYP2C19 loss-of-function (...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xuewei, Johnston, S. Claiborne, Wang, Anxin, Xu, Qin, Bath, Philip M., Pan, Yuesong, Li, Hao, Lin, Jinxi, Wang, Yilong, Zhao, Xingquan, Li, Zixiao, Jiang, Yong, Liu, Liping, Xu, Anding, Jing, Jing, Meng, Xia, Wang, Yongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245195/
https://www.ncbi.nlm.nih.gov/pubmed/37279000
http://dx.doi.org/10.1001/jamanetworkopen.2023.17037
_version_ 1785054809300140032
author Xie, Xuewei
Johnston, S. Claiborne
Wang, Anxin
Xu, Qin
Bath, Philip M.
Pan, Yuesong
Li, Hao
Lin, Jinxi
Wang, Yilong
Zhao, Xingquan
Li, Zixiao
Jiang, Yong
Liu, Liping
Xu, Anding
Jing, Jing
Meng, Xia
Wang, Yongjun
author_facet Xie, Xuewei
Johnston, S. Claiborne
Wang, Anxin
Xu, Qin
Bath, Philip M.
Pan, Yuesong
Li, Hao
Lin, Jinxi
Wang, Yilong
Zhao, Xingquan
Li, Zixiao
Jiang, Yong
Liu, Liping
Xu, Anding
Jing, Jing
Meng, Xia
Wang, Yongjun
author_sort Xie, Xuewei
collection PubMed
description IMPORTANCE: The Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial showed that ticagrelor-aspirin combination therapy reduced the risk of stroke compared with a clopidogrel-aspirin combination among carriers of CYP2C19 loss-of-function (LOF) alleles after a transient ischemic attack (TIA) or minor ischemic stroke. However, the association between the degree of CYP2C19 LOF and ideal treatment allocation remains unknown. OBJECTIVE: To investigate whether the efficacy and safety of ticagrelor-aspirin vs clopidogrel-aspirin are consistent with the expected degree of CYP2C19 LOF after TIA or minor stroke. DESIGN, SETTING, AND PARTICIPANTS: CHANCE-2 was a multicenter, double-blind, double-dummy, placebo-controlled randomized clinical trial. Patients were enrolled at 202 centers in China from September 23, 2019, through March 22, 2021. Patients with at least two *2 or *3 alleles (*2/*2, *2/*3, or *3/*3) according to point-of-care genotyping were classified as “poor metabolizers,” and those with one *2 or *3 allele (*1/*2 or *1/*3) were classified as “intermediate metabolizers.” INTERVENTIONS: Patients were randomly assigned in a 1:1 ratio to receive ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-90) or clopidogrel (300-mg loading dose on day 1 followed by 75 mg/d for days 2-90). All patients received aspirin (75- to 300-mg loading dose followed by 75 mg/d for 21 days). MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a new ischemic or hemorrhagic stroke. The secondary efficacy outcome was a composite of new clinical vascular events and individual ischemic stroke events within 3 months. The primary safety outcome was severe or moderate bleeding. Analyses were performed according to the intention-to-treat principle. RESULTS: Of the 6412 patients enrolled, the median age was 64.8 years (IQR, 57.0-71.4 years), and 4242 patients (66.2%) were men. Of the 6412 patients, 5001 (78.0%) were intermediate metabolizers, and 1411 (22.0%) were poor metabolizers. The primary outcome occurred less often with ticagrelor-aspirin vs clopidogrel-aspirin, irrespective of metabolizer status (6.0% [150 of 2486] vs 7.6% [191 of 2515]; hazard ratio [HR], 0.78 [95% CI, 0.63-0.97] among intermediate metabolizers and 5.7% [41 of 719] vs 7.5% [52 of 692]; HR, 0.77 [95% CI, 0.50-1.18] among poor metabolizers; P = .88 for interaction). Patients taking ticagrelor-aspirin had a higher risk of any bleeding event compared with those taking clopidogrel-aspirin, irrespective of metabolizer status: 5.4% (134 of 2486) vs 2.6% (66 of 2512) (HR, 2.14 [95% CI, 1.59-2.89]) among intermediate metabolizers and 5.0% (36 of 719) vs 2.0% (14 of 692) (HR, 2.99 [95% CI, 1.51-5.93]) among poor metabolizers (P = .66 for interaction). CONCLUSIONS AND RELEVANCE: This prespecified analysis of a randomized clinical trial found no difference in treatment effect between poor and intermediate CYP2C19 metabolizers. The relative clinical efficacy and safety of ticagrelor-aspirin vs clopidogrel-aspirin were consistent across CYP2C19 genotypes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04078737
format Online
Article
Text
id pubmed-10245195
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-102451952023-06-08 Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial Xie, Xuewei Johnston, S. Claiborne Wang, Anxin Xu, Qin Bath, Philip M. Pan, Yuesong Li, Hao Lin, Jinxi Wang, Yilong Zhao, Xingquan Li, Zixiao Jiang, Yong Liu, Liping Xu, Anding Jing, Jing Meng, Xia Wang, Yongjun JAMA Netw Open Original Investigation IMPORTANCE: The Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial showed that ticagrelor-aspirin combination therapy reduced the risk of stroke compared with a clopidogrel-aspirin combination among carriers of CYP2C19 loss-of-function (LOF) alleles after a transient ischemic attack (TIA) or minor ischemic stroke. However, the association between the degree of CYP2C19 LOF and ideal treatment allocation remains unknown. OBJECTIVE: To investigate whether the efficacy and safety of ticagrelor-aspirin vs clopidogrel-aspirin are consistent with the expected degree of CYP2C19 LOF after TIA or minor stroke. DESIGN, SETTING, AND PARTICIPANTS: CHANCE-2 was a multicenter, double-blind, double-dummy, placebo-controlled randomized clinical trial. Patients were enrolled at 202 centers in China from September 23, 2019, through March 22, 2021. Patients with at least two *2 or *3 alleles (*2/*2, *2/*3, or *3/*3) according to point-of-care genotyping were classified as “poor metabolizers,” and those with one *2 or *3 allele (*1/*2 or *1/*3) were classified as “intermediate metabolizers.” INTERVENTIONS: Patients were randomly assigned in a 1:1 ratio to receive ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-90) or clopidogrel (300-mg loading dose on day 1 followed by 75 mg/d for days 2-90). All patients received aspirin (75- to 300-mg loading dose followed by 75 mg/d for 21 days). MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a new ischemic or hemorrhagic stroke. The secondary efficacy outcome was a composite of new clinical vascular events and individual ischemic stroke events within 3 months. The primary safety outcome was severe or moderate bleeding. Analyses were performed according to the intention-to-treat principle. RESULTS: Of the 6412 patients enrolled, the median age was 64.8 years (IQR, 57.0-71.4 years), and 4242 patients (66.2%) were men. Of the 6412 patients, 5001 (78.0%) were intermediate metabolizers, and 1411 (22.0%) were poor metabolizers. The primary outcome occurred less often with ticagrelor-aspirin vs clopidogrel-aspirin, irrespective of metabolizer status (6.0% [150 of 2486] vs 7.6% [191 of 2515]; hazard ratio [HR], 0.78 [95% CI, 0.63-0.97] among intermediate metabolizers and 5.7% [41 of 719] vs 7.5% [52 of 692]; HR, 0.77 [95% CI, 0.50-1.18] among poor metabolizers; P = .88 for interaction). Patients taking ticagrelor-aspirin had a higher risk of any bleeding event compared with those taking clopidogrel-aspirin, irrespective of metabolizer status: 5.4% (134 of 2486) vs 2.6% (66 of 2512) (HR, 2.14 [95% CI, 1.59-2.89]) among intermediate metabolizers and 5.0% (36 of 719) vs 2.0% (14 of 692) (HR, 2.99 [95% CI, 1.51-5.93]) among poor metabolizers (P = .66 for interaction). CONCLUSIONS AND RELEVANCE: This prespecified analysis of a randomized clinical trial found no difference in treatment effect between poor and intermediate CYP2C19 metabolizers. The relative clinical efficacy and safety of ticagrelor-aspirin vs clopidogrel-aspirin were consistent across CYP2C19 genotypes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04078737 American Medical Association 2023-06-06 /pmc/articles/PMC10245195/ /pubmed/37279000 http://dx.doi.org/10.1001/jamanetworkopen.2023.17037 Text en Copyright 2023 Xie X et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Xie, Xuewei
Johnston, S. Claiborne
Wang, Anxin
Xu, Qin
Bath, Philip M.
Pan, Yuesong
Li, Hao
Lin, Jinxi
Wang, Yilong
Zhao, Xingquan
Li, Zixiao
Jiang, Yong
Liu, Liping
Xu, Anding
Jing, Jing
Meng, Xia
Wang, Yongjun
Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title_full Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title_fullStr Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title_full_unstemmed Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title_short Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial
title_sort association of cyp2c19 loss-of-function metabolizer status with stroke risk among chinese patients treated with ticagrelor-aspirin vs clopidogrel-aspirin: a prespecified secondary analysis of a randomized clinical trial
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245195/
https://www.ncbi.nlm.nih.gov/pubmed/37279000
http://dx.doi.org/10.1001/jamanetworkopen.2023.17037
work_keys_str_mv AT xiexuewei associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT johnstonsclaiborne associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT wanganxin associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT xuqin associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT bathphilipm associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT panyuesong associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT lihao associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT linjinxi associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT wangyilong associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT zhaoxingquan associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT lizixiao associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT jiangyong associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT liuliping associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT xuanding associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT jingjing associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT mengxia associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial
AT wangyongjun associationofcyp2c19lossoffunctionmetabolizerstatuswithstrokeriskamongchinesepatientstreatedwithticagreloraspirinvsclopidogrelaspirinaprespecifiedsecondaryanalysisofarandomizedclinicaltrial